Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Corcept Therapeutics Inc's Business Segments
Corcept Therapeutics Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Reportable Segments
-
Largest Segment
-
Total Revenue
$ 256
Regions Reported
-
Revenue by Product & Service Category -
- Hypercortisolism Products81.4%
- Lifyorli18.6%
Revenue by Product & Service Category -
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Hypercortisolism Products | $ 209 | 81.4% |
| Lifyorli | $ 48 | 18.6% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Corcept Therapeutics Inc
Corcept Therapeutics Inc. is an American pharmaceutical company that is focused on the discovery, development, and commercialization of drugs that target cortisol to treat severe metabolic, oncologic, and psychiatric disorders.
The company was founded in 1998 by Dr. Joseph Belanoff and is headquartered in Menlo Park, California. Its primary drug is mifepristone, which is an oral medication that is used to treat Cushing's Syndrome, a rare hormonal disorder that is caused by the overproduction of cortisol. Mifepristone has been FDA-approved since 2012 and is marketed under the brand name Korlym.
In addition to Korlym, Corcept has a pipeline of proprietary drugs, including CORT125134, CORT118335, and CORT125281 that are currently in various stages of clinical development. These drugs target several different indications, such as triple-negative breast cancer, ovarian cancer, and Cushing's Syndrome.
Corcept has a seasoned management team that has extensive experience in the biopharmaceutical industry. The company is led by Dr. Joseph Belanoff, who serves as its Chief Executive Officer and President. He co-founded the company and has a long history of working in the field of psychiatry and endocrinology. The company's Chief Medical Officer is Dr. Paris Panayiotopoulos, who has over 25 years of experience in clinical development and is responsible for overseeing the clinical development of Corcept's drug candidates.
Corcept has a strong intellectual property portfolio, with numerous patents and patent applications that cover its proprietary drugs and technologies. The company also has collaborations with several academic institutions and research organizations to advance its drug development programs.
In 2020, Corcept reported total revenues of $421 million and had a net income of $230.4 million. The company has a market capitalization of approximately $6 billion as of August 2021 and is publicly traded on the NASDAQ stock exchange under the ticker symbol CORT.
The company was founded in 1998 by Dr. Joseph Belanoff and is headquartered in Menlo Park, California. Its primary drug is mifepristone, which is an oral medication that is used to treat Cushing's Syndrome, a rare hormonal disorder that is caused by the overproduction of cortisol. Mifepristone has been FDA-approved since 2012 and is marketed under the brand name Korlym.
In addition to Korlym, Corcept has a pipeline of proprietary drugs, including CORT125134, CORT118335, and CORT125281 that are currently in various stages of clinical development. These drugs target several different indications, such as triple-negative breast cancer, ovarian cancer, and Cushing's Syndrome.
Corcept has a seasoned management team that has extensive experience in the biopharmaceutical industry. The company is led by Dr. Joseph Belanoff, who serves as its Chief Executive Officer and President. He co-founded the company and has a long history of working in the field of psychiatry and endocrinology. The company's Chief Medical Officer is Dr. Paris Panayiotopoulos, who has over 25 years of experience in clinical development and is responsible for overseeing the clinical development of Corcept's drug candidates.
Corcept has a strong intellectual property portfolio, with numerous patents and patent applications that cover its proprietary drugs and technologies. The company also has collaborations with several academic institutions and research organizations to advance its drug development programs.
In 2020, Corcept reported total revenues of $421 million and had a net income of $230.4 million. The company has a market capitalization of approximately $6 billion as of August 2021 and is publicly traded on the NASDAQ stock exchange under the ticker symbol CORT.
Corcept Therapeutics Inc. is a biopharmaceutical company committed to the discovery, development, and commercialization of innovative therapies that address severe and complex illnesses. The companys strategic focus is on identifying and developing medications primarily targeting conditions associated with excessive cortisol production, certain cancers, and severe psychiatric disorders.
Segments
Corcept operates within three main segments:
1. Cushings Syndrome:
- This segment revolves around the treatment of Cushings syndrome, a rare endocrine disorder caused by prolonged exposure to high cortisol levels. The main products developed under this segment are designed to manage and mitigate the effects of excessive cortisol in patients.
- Key Products:
- Korlym (mifepristone): This drug is indicated for the treatment of patients with Cushings syndrome who have type 2 diabetes or glucose intolerance. Korlym functions as a glucocorticoid receptor antagonist, effectively reducing cortisol levels, which can lead to improved metabolic parameters and quality of life in affected patients.
- Relacorilant: This investigational drug is also targeted to control cortisol levels but is differentiated by its potentially more favorable side effect profile compared to Korlym. It is being researched for its effectiveness in both Cushings syndrome and other indications where cortisol modulation is beneficial.
2. Oncology:
- Corcept is involved in developing therapies for various cancers, focusing on understanding the relationship between cortisol and tumor biology. High cortisol levels can influence tumor progression and response to treatments.
- Key Products:
- Exicure: Exicure is being investigated for the treatment of solid tumors, including but not limited to pancreatic, ovarian, and lung cancers. This product leverages the company’s expertise in cortisol modulation and its impact on tumor biology.
- Relacorilant: In addition to its use in Cushings syndrome, relacorilant is under evaluation in clinical trials for its potential in oncology, particularly its role in treating tumors influenced by cortisol levels.
3. Psychiatry:
- This segment targets severe psychiatric disorders, a field of growing interest due to the complex interplay between cortisol dysregulation and mental health illnesses.
- Key Product:
- CORT125281: This compound is in development for the treatment of major depressive disorder, generalized anxiety disorder, and bipolar disorder. By modulating cortisol levels, CORT125281 aims to provide relief from symptoms associated with these debilitating conditions, addressing a significant unmet need in psychiatric care.
Products
Corcept’s product portfolio includes:
1. Korlym: FDA-approved for use in patients with Cushings syndrome, facilitating better glucose metabolism and reducing associated health risks.
2. Relacorilant: An investigational drug that boasts a dual indication in treating Cushings syndrome and oncology applications, currently undergoing various stages of clinical testing.
3. Exicure: An experimental treatment for multiple cancer types, underlining the company’s commitment to oncology and the unique relationships between cortisol, tumor biology, and treatment efficacy.
4. CORT125281: Focused on psychiatric disorders, it is designed to address the link between cortisol and mood regulation, presenting a novel approach in a therapeutic landscape rich in existing but often inadequate treatments.
Services
Corcept Therapeutics provides a range of services that enhance its operational viability and product efficacy:
1. Clinical Trials: The company actively runs clinical trials to evaluate the effectiveness and safety of its products. This involves maintaining partnerships with leading medical institutions globally to ensure robust clinical data collection and analysis.
2. Marketing and Sales: Using a dedicated sales force and a network of distributors, Corcept promotes its products, offering education and support to healthcare providers and patients to optimize therapeutic outcomes.
3. Regulatory Affairs: Corcept’s regulatory affairs team diligently works to comply with varying international health regulations, ensuring that its products meet the necessary safety and efficacy standards before reaching the market.
Conclusion
Corcept Therapeutics Inc. represents an innovative leader in addressing some of the most challenging medical conditions through its focus on cortisol modulation. With a commitment to research and development across Cushings syndrome, oncology, and severe psychiatric disorders, the company harnesses its scientific expertise to improve the lives of patients affected by these severe illnesses. The comprehensive approach to drug development and commercialization positions Corcept as a vital player in the pharmaceutical landscape.
Segments
Corcept operates within three main segments:
1. Cushings Syndrome:
- This segment revolves around the treatment of Cushings syndrome, a rare endocrine disorder caused by prolonged exposure to high cortisol levels. The main products developed under this segment are designed to manage and mitigate the effects of excessive cortisol in patients.
- Key Products:
- Korlym (mifepristone): This drug is indicated for the treatment of patients with Cushings syndrome who have type 2 diabetes or glucose intolerance. Korlym functions as a glucocorticoid receptor antagonist, effectively reducing cortisol levels, which can lead to improved metabolic parameters and quality of life in affected patients.
- Relacorilant: This investigational drug is also targeted to control cortisol levels but is differentiated by its potentially more favorable side effect profile compared to Korlym. It is being researched for its effectiveness in both Cushings syndrome and other indications where cortisol modulation is beneficial.
2. Oncology:
- Corcept is involved in developing therapies for various cancers, focusing on understanding the relationship between cortisol and tumor biology. High cortisol levels can influence tumor progression and response to treatments.
- Key Products:
- Exicure: Exicure is being investigated for the treatment of solid tumors, including but not limited to pancreatic, ovarian, and lung cancers. This product leverages the company’s expertise in cortisol modulation and its impact on tumor biology.
- Relacorilant: In addition to its use in Cushings syndrome, relacorilant is under evaluation in clinical trials for its potential in oncology, particularly its role in treating tumors influenced by cortisol levels.
3. Psychiatry:
- This segment targets severe psychiatric disorders, a field of growing interest due to the complex interplay between cortisol dysregulation and mental health illnesses.
- Key Product:
- CORT125281: This compound is in development for the treatment of major depressive disorder, generalized anxiety disorder, and bipolar disorder. By modulating cortisol levels, CORT125281 aims to provide relief from symptoms associated with these debilitating conditions, addressing a significant unmet need in psychiatric care.
Products
Corcept’s product portfolio includes:
1. Korlym: FDA-approved for use in patients with Cushings syndrome, facilitating better glucose metabolism and reducing associated health risks.
2. Relacorilant: An investigational drug that boasts a dual indication in treating Cushings syndrome and oncology applications, currently undergoing various stages of clinical testing.
3. Exicure: An experimental treatment for multiple cancer types, underlining the company’s commitment to oncology and the unique relationships between cortisol, tumor biology, and treatment efficacy.
4. CORT125281: Focused on psychiatric disorders, it is designed to address the link between cortisol and mood regulation, presenting a novel approach in a therapeutic landscape rich in existing but often inadequate treatments.
Services
Corcept Therapeutics provides a range of services that enhance its operational viability and product efficacy:
1. Clinical Trials: The company actively runs clinical trials to evaluate the effectiveness and safety of its products. This involves maintaining partnerships with leading medical institutions globally to ensure robust clinical data collection and analysis.
2. Marketing and Sales: Using a dedicated sales force and a network of distributors, Corcept promotes its products, offering education and support to healthcare providers and patients to optimize therapeutic outcomes.
3. Regulatory Affairs: Corcept’s regulatory affairs team diligently works to comply with varying international health regulations, ensuring that its products meet the necessary safety and efficacy standards before reaching the market.
Conclusion
Corcept Therapeutics Inc. represents an innovative leader in addressing some of the most challenging medical conditions through its focus on cortisol modulation. With a commitment to research and development across Cushings syndrome, oncology, and severe psychiatric disorders, the company harnesses its scientific expertise to improve the lives of patients affected by these severe illnesses. The comprehensive approach to drug development and commercialization positions Corcept as a vital player in the pharmaceutical landscape.